Fayez Sarofim & Co Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Fayez Sarofim & Co increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 395,297 shares of the company's stock after purchasing an additional 27,422 shares during the quarter. Fayez Sarofim & Co's holdings in Eli Lilly and Company were worth $305,170,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of LLY. Principal Financial Group Inc. lifted its holdings in Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the period. Invst LLC grew its holdings in Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after purchasing an additional 189 shares during the period. McIlrath & Eck LLC increased its position in shares of Eli Lilly and Company by 3.4% in the third quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock valued at $426,000 after buying an additional 16 shares in the last quarter. Virtu Financial LLC raised its stake in shares of Eli Lilly and Company by 111.7% during the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock worth $5,786,000 after buying an additional 3,446 shares during the period. Finally, SOA Wealth Advisors LLC. lifted its position in shares of Eli Lilly and Company by 2.4% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company's stock valued at $766,000 after buying an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on LLY shares. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Guggenheim decreased their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,017.00.

Eli Lilly and Company Stock Up 3.8 %

Shares of Eli Lilly and Company stock traded up $31.69 during trading hours on Thursday, reaching $861.11. 2,936,578 shares of the company were exchanged, compared to its average volume of 3,430,652. The firm has a market cap of $816.48 billion, a PE ratio of 73.54, a PEG ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock's fifty day moving average is $826.81 and its 200 day moving average is $819.07.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.